Inspire will be shedding tears over Prolacria failure

Date January 25, 2010

The story of dry eye treatment Prolacria is long and convoluted, and unfortunately one that looks unlikely to have a happy ending. Last week, its developer Inspire Pharmaceuticals, which has been trying to win approval from the FDA since 2003, announced that a fourth phase III trial had failed; the product must surely now be heading for the R&D dustbin.

Inspire cannot be faulted for effort; despite two approvable letters over the years it has pushed on, even validating a new clinical endpoint in an attempt to get the product to the market, and as such expectations were pretty low for this product. Attention will now turn to the remainder of Inspire’s pipeline which should generate some interesting data in the coming months, and hopefully compensate for the loss of Prolacria.

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2018 EP Vantage Ltd